Bevacizumab News and Research

RSS
Bevacizumab is a recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine. Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels.
Anticancer drug restores hearing in neurofibromatosis patients

Anticancer drug restores hearing in neurofibromatosis patients

Popular kidney cancer drugs do not reduce incidence of recurrence

Popular kidney cancer drugs do not reduce incidence of recurrence

Research unveils standard front-line treatment for advanced ovarian cancer

Research unveils standard front-line treatment for advanced ovarian cancer

Study shows high cost, high side effects and little gain for chemotherapy in older mCRC patients

Study shows high cost, high side effects and little gain for chemotherapy in older mCRC patients

PD-L1 inhibition well-tolerated, active in metastatic RCC

PD-L1 inhibition well-tolerated, active in metastatic RCC

Bevacizumab extends survival of pleural mesothelioma patients

Bevacizumab extends survival of pleural mesothelioma patients

Pathologic complete response after presurgery chemotherapy increases overall survival for TNBC patients

Pathologic complete response after presurgery chemotherapy increases overall survival for TNBC patients

Researchers find ranibizumab drug as effective alternative to laser therapy for treating diabetic retinopathy

Researchers find ranibizumab drug as effective alternative to laser therapy for treating diabetic retinopathy

New campaign raises awareness of City of Hope's life-saving mission and impact

New campaign raises awareness of City of Hope's life-saving mission and impact

Liposomal sizing and the Coulter principle: an interview with Professor Melvin E. Klegerman

Liposomal sizing and the Coulter principle: an interview with Professor Melvin E. Klegerman

Early trial results in lung cancer

Early trial results in lung cancer

NAM announces election of three new members from UC San Diego School of Medicine

NAM announces election of three new members from UC San Diego School of Medicine

DelMar reports positive data from preclinical study of VAL-083 for treatment of ovarian cancer

DelMar reports positive data from preclinical study of VAL-083 for treatment of ovarian cancer

Specific biomarker predicts which HER2-negative breast cancer patients respond to targeted therapy

Specific biomarker predicts which HER2-negative breast cancer patients respond to targeted therapy

DelMar presents updated VAL-083 Phase I/II trial data at GBM2015 meeting

DelMar presents updated VAL-083 Phase I/II trial data at GBM2015 meeting

Risk for endophthalmitis no higher with Avastin, finds study

Risk for endophthalmitis no higher with Avastin, finds study

DME treatment evolves in favour of intravitreal anti-VEGF injections

DME treatment evolves in favour of intravitreal anti-VEGF injections

Low BMI linked to poorer survival in advanced colorectal cancer

Low BMI linked to poorer survival in advanced colorectal cancer

Study may predict which glioblastoma patients may respond well to dasatinib drug treatment

Study may predict which glioblastoma patients may respond well to dasatinib drug treatment

No overall survival benefit for bevacizumab in ovarian cancer

No overall survival benefit for bevacizumab in ovarian cancer